Pepaxto (Melphalan Flufenamide) – Myeloma | HongKong DengYue Medicine
- Generic Name/Brand Name: Melphalan flufenamide / Pepaxto®
- Indications: Myeloma
- Dosage Form: Injection
- Specification: 20 mg × 1 vial/box
Melphalan Flufenamide Application Scope
Pepaxto® is indicated, in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody.

Melphalan Flufenamide Characteristics
Ingredients: Melphalan flufenamide
Properties: Alkylating agent; peptide–drug conjugate (PDC)
Packaging Specification: 20 mg × 1 vial/box (lyophilized powder for injection)
Storage: Store at 2–8°C; protect from light
Expiry Date: As per package label
Executive Standard: FDA/EMA approval standards
Approval Number: FDA NDA 214383 (withdrawn in US in 2022, still approved in EU)
Date of Revision: Latest EMA SmPC: July 2022
Manufacturer: Oncopeptides AB (Sweden)
Guidelines for the Use of Pepaxto
Dosage and Administration:
Recommended Dose: 40 mg IV every 28 days (Day 1 of each cycle), combined with dexamethasone
Administration: Intravenous infusion over 30 minutes
Missed Dose: Administer as soon as possible; adjust schedule as needed
Adverse Reactions:
Common Adverse Reactions:
Fatigue
Nausea, diarrhea
Cytopenias (anemia, thrombocytopenia, neutropenia)
Pyrexia
Serious Adverse Reactions:
Severe thrombocytopenia
Neutropenia with infections
Secondary malignancies
Contraindications:
Hypersensitivity to excipients
Pregnancy and breastfeeding
Precautions:
Monitor blood counts regularly
Risk of severe cytopenias
Use contraception during and after treatment
Adjust dose for severe toxicity
Melphalan Flufenamide Interactions
Limited data on drug–drug interactions
Caution with myelosuppressive agents (additive hematologic toxicity)
No major CYP-mediated interactions identified
Note:
- If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
- This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.










Reviews
There are no reviews yet.